Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern TimeGERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (
NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2026 financial results after market close on Monday, November 9, 2026.
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic PancreasPairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients
Senseonics To Participate in Upcoming Institutional Investor ConferencesGERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (
NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences. Details on the Company’s participation appear below:
Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial ResultsGERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (
NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced second quarter 2026 financial results and provided a business update.
